Skip to content
Research Article Open access CC BY 4.0

Assessment of Antibiotic Resistance Pattern of Bacteria Prevalent during COVID-19 Pandemic

Khaled Abdulrahman Aldhwaihi, Saud M. Alsanad, Abdulrahman Hadi Almutiri, Saad Aldoihi

Journal of Pharmaceutical Research International · pp. 117–127 · Published 14 Dec 2021

10.9734/jpri/2021/v33i57A33975

Abstract

Owing to disparities in the intensity of the breakouts, state and federal regulations, accessible means, cultural elements, and social consciousness, the global reaction to the COVID-19 pandemic has been varied. The COVID-19 pandemic, on the other hand, has had an impact on all parts of society, notably efforts to combat antimicrobial resistance (AMR). The pandemic has highlighted that a greater burden on medical infrastructure can contribute to higher, often unnecessary antibiotic usage and a de-prioritization of antimicrobial stewardship and surveillance (AMS). The focus of this research is to see if there is a growth in antibiotic resistance during the covid-19 pandemic in the King Salman Hospital in Riyadh, Saudi Arabia, and to investigate the subcomponent that leads to antibiotic resistance. This is a comprehensive review of patients hospitalized at the King Salman Hospital in Riyadh, Saudi Arabia, who were admitted to the Intensive Care Unit (ICU) during the first wave of the covid-19 pandemic, which occurred between March and August 2020. An analysis of the case dataset was performed to determine the rise in antibiotic resistance and relate it to resistant cases before the pandemic (September 2019 to February 2020). Before and throughout the pandemic, fifteen kinds of bacteria were found, with K. pneumonia being the most prevalent bacteria (49; 30.6%), and Ac. Baum/haem being the most removable bacteria during the pandemic (74; 37.3%). Cephalosporin antibiotics, in notably cefotaxime and ceftazidime (100%), cefazolin (96.3%), ceftriaxone (96%), cefuroxime and ceftazidime (95%), cefotaxime ((94.7%). These antibiotics also had the same amount of resistance during the pandemic. In pre-covid-19 and during covid-19, these findings were congruent with the penicillin antibiotics class, ampicillin, and piperacillin (96.3% and 92.1%), accordingly. It is presently uncertain if COVID-19 patients would develop new or growing antibiotic resistance in locations with low historical prevalence, but this should be investigated in retrospective and future clinical and microbiology research.

COVID-19 pandemic antimicrobial resistance antibiotic

References (33)

  1. 1 Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study [DOI]
  2. 2 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges [DOI]
  3. 3 Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing [DOI]
  4. 4 Co-infections in people with COVID-19: a systematic review and meta-analysis [DOI]
  5. 5 Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis [DOI]
  6. 6 Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study [DOI]
  7. 7 Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting [DOI]
  8. 8 Coronavirus disease 2019 (COVID-19): a clinical update [DOI]
  9. 9 The COVID-19 Pandemic: Effects on Low- and Middle-Income Countries [DOI]
  10. 10 Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status [DOI]
  11. 11 Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain [DOI]
  12. 12 Empiric Antibacterial Therapy and Community-onset Bacterial Coinfection in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19): A Multi-hospital Cohort Study [DOI]
  13. 13 COVID-19: don't neglect antimicrobial stewardship principles! [DOI]
  14. 14 Tackling antimicrobial resistance in the COVID-19 pandemic [DOI]
  15. 15 Continued high rates of antibiotic prescribing to adults with respiratory tract infection: survey of 568 UK general practices [DOI]
  16. 16 Antimicrobial use, drug-resistant infections and COVID-19 [DOI]
  17. 17 Coronavirus Disease 2019, Superinfections, and Antimicrobial Development: What Can We Expect? [DOI]
  18. 18 Antibiotic use in patients with COVID-19: a ‘snapshot’ Infectious Diseases International Research Initiative (ID-IRI) survey [DOI]
  19. 19 Antibiotics and antimicrobial resistance in the COVID-19 era: Perspective from resource-limited settings [DOI]
  20. 20 Inappropriate antibiotic prescription for respiratory tract indications: most prominent in adult patients [DOI]
  21. 21 Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United States [DOI]
  22. 22 Coronavirus Disease 2019 and Antimicrobial Resistance: Parallel and Interacting Health Emergencies [DOI]
  23. 23 Antibiotic prescription during the COVID-19 pandemic: A biphasic pattern [DOI]
  24. 24 Antibiotic Consumption and Stewardship at a Hospital outside of an Early Coronavirus Disease 2019 Epicenter [DOI]
  25. 25 Impact of COVID-19 on pneumonia-focused antibiotic use at an academic medical center [DOI]
  26. 26 Antimicrobial stewardship: a COVID casualty? [DOI]
  27. 27 SARS-CoV-2, BACTERIAL CO-INFECTIONS, AND AMR: THE DEADLY TRIO IN COVID-19? [DOI]
  28. 28 Antimicrobial prescribing practices at a tertiary-care center in patients diagnosed with COVID-19 across the continuum of care [DOI]
  29. 29 Underestimation of co-infections in COVID-19 due to non-discriminatory use of antibiotics [DOI]
  30. 30 Pediatric antimicrobial stewardship in the COVID-19 outbreak [DOI]
  31. 31 Impact of COVID-19 on Madrid hospital system [DOI]
  32. 32 COVID-19 treatment in sub-Saharan Africa: If the best is not available, the available becomes the best [DOI]
  33. 33 Perceived Challenges of COVID-19 Infection Prevention and Control Preparedness: A Multinational Survey [DOI]

Cited by 5

Bacterial co-infections and antimicrobial resistance associated with the Coronavirus Disease 2019 infection

Addisu D. Teklemariam, Anwar M. Hashem, Saber H. Saber · Biotechnology and Genetic Engineering Reviews · 2022

Antibiotic Resistance during COVID-19: A Systematic Review

Hadi Jaber Al Sulayyim, Rohani Ismail, Abdullah Al Hamid · International Journal of Environmental Research and Public Health · 2022

Antibiotic resistance before, during, and after the COVID-19 pandemic: a retrospective study

Hadi Al Sulayyim, Rohani Ismail, Abdullah Al Hamid · The Journal of Infection in Developing Countries · 2024

Showing 3 of 5 known citations — external sources report more than can currently be individually listed.

Related research

Article metrics

Real usage data collected on this platform.

1

Page views

0

PDF downloads

0

Outbound clicks

5

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.